trending Market Intelligence /marketintelligence/en/news-insights/trending/3uK4fbLh1ozSTc99J5ocEQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Biocartis raises €80M via equity placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Biocartis raises €80M via equity placement

Biocartis Group NV raised about €80 million in gross proceeds through a private placement via an accelerated bookbuild offering of 6.4 million new shares.

The company offered the shares, representing about 14.33% of its outstanding stock, at 12.50 apiece.

Biocartis plans to use the net proceeds to fund the expansion of Idylla test menu and applications, its sales and marketing activities and the ongoing increase of its cartridge manufacturing capacity. It also intends to use the funds for working capital and other general corporate purposes.

The payment and delivery of the shares is expected to take place on Dec. 1 and an application will be made to admit the new shares to trading on the regulated market of Euronext Brussels at the same time.

J.P. Morgan, Degroof Petercam, KBC Securities and Kempen acted as joint book runners in the offering.